Overview
- Editors:
-
-
Brian I. Carr
-
Dokuz Eylul University, Izmir Biomedicine and Genome Center Dokuz Eylul University, Izmir, Turkey
- Provides the reader with a clear understanding of the many mechanisms involved in carcinogenesis of the liver
- Comprehensive and detailed review of how to diagnose and treat hepatocellular carcinoma
- Written by international leaders in the field Updated and enhanced new edition covering topics such as global epidemiology, environmental carcinogens and diet, CT imaging, vascular radiology, and psychological factors
- Vital resource for today's hepatologists and medical and surgical oncologists
- Includes supplementary material: sn.pub/extras
About this book
• Hepatocellular carcinoma (HCC) used to be regarded as a rare disease. However, the increasing numbers of chronic HCC carriers in the U.S. and subsequent increased incidences of HCC seen in most large medical centers means that it is no longer an uncommon disease for gastroenterologists or oncologists to encounter and its incidence and epidemiology are changing. During this exciting time in the field of HCC basic science and clinical management, many changes are simultaneously occurring at multiple levels of our understanding and management of the disease. Suddenly, there are several new choices of therapy to offer patients. Hepatocellular Carcinoma, 3rd edition addresses this fast-changing disease and gives the reader a clearer understanding of the many mechanisms involved in carcinogenesis of the liver. This comprehensive and detailed review of how to diagnose and treat hepatocellular carcinoma is written by international leaders in the field, covering both clinical treatment choices and the basic science underlying HCC development. Updated and enhanced from the last edition in 2009, Hepatocellular Carcinoma, 3rd edition features 12 new chapters including discussion of molecular markers, molecular hepatocarcinogenesis, microenvironment, heterogeneity, the new and exciting contributions of immunotherapy, and updates on the major effective hepatitis therapies that will transform HCC incidence and perhaps also the therapy. This cutting-edge text is a vital resource and must-have for today’s hepatologists and medical and surgical oncologists.
"This is a well written text and should be a good reference book for those who see patients with HCC.." - Practical Gastroenterology
"...a useful tool for both physicians and surgeons with a specific interest in the management of patients with HCC." - Digestive and Liver Disease
Similar content being viewed by others
Table of contents (37 chapters)
-
-
Causes, Biological and Molecular Bases of HCC
-
-
- Donna L. White, Fasiha Kanwal, Li Jiao, Hashem B. El-Serag
Pages 3-24
-
-
- Hani Alotaibi, Nese Atabey, Kasım Diril, Esra Erdal, Mehmet Ozturk
Pages 43-63
-
-
- Anuradha Budhu, Xin Wei Wang
Pages 93-112
-
- Jean-Charles Nault, Jessica Zucman-Rossi
Pages 113-119
-
-
- Nicolas Goossens, Ismail Labgaa, Augusto Villanueva
Pages 139-147
-
- Sven H. Loosen, Christoph Roderburg, Tom Luedde
Pages 149-155
-
- Antonio Mazzocca, Giovanni Ferraro, Giovanni Misciagna, Brian I. Carr
Pages 157-161
-
-
-
- Tobias Flecken, Robert Thimme
Pages 199-210
-
- Evgeny V. Denisov, Tatiana S. Gerashchenko, Marina V. Zavyalova, Vasiliy N. Manskikh, Evgeny L. Choinzonov, Nadezhda V. Cherdyntseva et al.
Pages 211-228
-
- David J. Pinato, Rohini Sharma
Pages 229-241
-
- Inbal Houri, Oren Shibolet
Pages 243-259
-
- Ryota Masuzaki, Tatsuo Kanda, Haruhiko Yoshida, Naoya Kato, Masao Omata
Pages 261-273
-
- Chadia L. Robertson, Devanand Sarkar, Arun J. Sanyal
Pages 275-286
Editors and Affiliations
-
Dokuz Eylul University, Izmir Biomedicine and Genome Center Dokuz Eylul University, Izmir, Turkey
Brian I. Carr
About the editor
Dr. Brian I. Carr is Professor of Medical Oncology, Thomas Jefferson University, Philadelphia and Professor, IRCCS de Bellis, National Institute for Digestive Diseases, Castellana Grotte (BA), Italy. Since 1977 he has devoted both his clinical activities and research science efforts to the clinical and scientific study of primary liver cancer (HCC or hepatocellular carcinoma). He has published more than 250 papers in peer-reviewed journals, over 350 abstracts and given a similar number of meeting presentations, written chapters in 36 books and edited 2 books. He is guest editor for the HCC special issue of Seminars in Oncology, Aug, 2012 and has written the chapter on HCC for the last 2 editions of Harrison’s Internal Medicine.